Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Escalated Photon IMRT or Proton Beam Therapy vs Standard RT with Temozolomide in Newly Diagnosed Glioblastoma
NCT02179086Phase 2Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2014
- Primary completion
- Jul 2025
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) (4 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival up to 18.3 months. Started Dec 2014; status: active, not recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02179086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179086.